Peer-influenced content. Sources you trust. No registration required. This is HCN.
Dana-Farber Cancer Institute
Latest clinical trial data suggests active monitoring may be a viable alternative to standard treatment for select low-risk DCIS patients, with comparable quality-of-life outcomes.
Oncology, Medical January 21st 2025
Clinical Advances in Hematology & Oncology
Explore groundbreaking trials from SABCS 2023, revealing the potential of sacituzumab govitecan and datopotamab deruxtecan in enhancing treatment paradigms for metastatic breast cancer, spotlighting pivotal advancements in antibody-drug conjugate therapy.
Oncology, Medical March 11th 2024
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS